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Acquired APC Resistance in Neurosurgical Patients May Not Be
a Risk Factor for Postoperative Deep Vein Thrombosis
*Johan R. Meinardi, M.D., *Cilia M. A. Henkens, M.D., Ph.D., &dagger;Pieter-Jan de Kam, M.Sc., and
*Jan Van der Meer, M.D., Ph.D.
*Division of Hemostasis, Thrombosis and Rheology, University Hospital, Groningen, and &dagger;Trial Coordination Centre, University
Hospital, Groningen, The Netherlands
Summary: Acquired resistance to activated protein C has
been reported during oral contraception and pregnancy. Its
thrombogenic potential was studied in 41 neurosurgical pa-
tients who were enrolled in the placebo group of a thrombo-
prophylaxis trial. Normalized activated protein C sensitivity
ratio (nAPC-SR), clotting activity of factors V and VIII, and
levels of protein C antigen were measured prior to and at days
3 and 7 after surgery. Bilateral venography was done in all
patients at days 8-10 to demonstrate deep vein thrombosis. A
lowered nAPC-SR was found in 76% (baseline), 80% (day 3),
and 88% (day 7) of patients. It was inversely related to factor
VIII clotting activity (p = .0003) and protein C antigen, (p =
.02). Deep vein thrombosis was demonstrated in 30% of pa-
tients with a normal nAPC-SR and in 23% of patients with a
lowered nAPC-SR. Pulmonary embolism was not observed.
Multivariate analysis did not identify a lowered nAPC-SR as a
thrombotic risk factor, in contrast with gender (women, p =
.02) and Quetelet index (&ge;25 kg/m, p = .006). Our data
provide no evidence that acquired activated protein C resis-
tance, frequently found in neurosurgical patients, contributes to
their high risk of postoperative deep vein thrombosis. Key
Words: Thromboembolism&mdash;Blood coagulation disorders&mdash;
APC resistance&mdash;Factor V&mdash;Neurosurgery.
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Hereditary resistance to activated protein C (APC) is
the most common genetic defect associated with an in-
creased risk of venous thromboembolism (1,2). In the
vast majority of affected individuals, APC resistance re-
sults from a single point mutation of the blood coagula-
tion factor V gene (factor V:QSO6 mutation or factor V
Leiden), which renders the activated form of factor V
less susceptible to proteolytic inactivation by APC (3).
Hereditary APC resistance is commonly demonstrated
by a lowered ratio of the activated partial thromboplastin
time (aPTT), which is measured in the presence and ab-
sence of APC, respectively (APC ratio) (4). It is most
reliably diagnosed by DNA analysis. Recently, a lowered
APC ratio, not due to the factor V:QSO6 mutation, has
been reported in women using oral contraceptives and in
pregnant women (5-7). Another study showed that
women who used third-generation oral contraceptives
were significantly less sensitive to APC than those using
second-generation oral contraceptives (8). These obser-
vations suggest acquired APC resistance. Its association
with known thrombotic risk factors has even been inter-
preted as the causal explanation of thrombosis in these
conditions (8,9).
Because surgery is another established risk factor for
venous thromboembolism, the question arises whether
acquired APC resistance contributes to the development
of postoperative venous thromboembolism. We con-
ducted a retrospective analysis of data derived from a
prospective, randomized thromboprophylaxis trial to es-
timate the incidence of acquired APC resistance and its
relation to postoperative venous thromboembolism.
PATIENTS AND METHODS
Patients
The study contained all patients in our center who
were enrolled in a double-blind, randomized, placebo-
controlled, multicenter trial that was designed to assess -
the efficacy and safety of the low molecular weight
heparin nadroparin calcium (FraxiparinTM, Sanofi, Paris,
France) in the prevention of venous thromboembolism
in neurosurgical patients (10). Consecutive patients
(age ~!18 years) were included who were undergoing
craniotomy or spinal column surgery because of tumor,
subarachnoidal bleeding, or clipping of a single aneurysm.
Written informed consent was obtained. The patients
were randomly assigned to subcutaneous treatment with
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nadoparin calcium or placebo from the first postopera-
tive day. All patients wore elastic compression stockings
from shortly before surgery until discharge. Patients who
underwent craniotomy were treated with dexamethasone
(16 mg daily) from 2 days before surgery until the sec-
ond postoperative day, when the dose was tapered. Hy-
drocortisone was given to patients with a pituitary tumor
from the evening before operation. Prior to discontinua-
tion of the trial medication (8 to 10 days after surgery)
bilateral venography was performed. It was performed
earlier if clinical suspicion of deep vein thrombosis
(DVT) was found and B-mode compression ultrasonog-
raphy was abnormal. Ventilation-perfusion lung scan-
ning was performed if pulmonary embolism was clini-
cally suspected.
Laboratory tests
Coagulation tests were performed on plasma samples
collected I day before surgery and on days 3 and 7 after
surgery. Nine-tenths volume of whole blood was mixed
with 1/lOth volume of trisodiumcitrate. Platelet-free
plasma was prepared by centrifugation for 10 minutes at
4,000 rpm, followed by 5 minutes at 14,000 rpm in a
microcentrifuge, and it was frozen at -80°C until assays
were performed. The APC ratio was measured using the
commercially available CoatestTM APC resistance kit
(Chromogenix AB, M61ndal, Sweden) and expressed as
normalized APC-sensitivity ratio (nAPC-SR) (4). The
normal range of nAPC-SR was 0.82-1.22, defined as
mean ± 2 SD in healthy volunteers. Clotting activity of
factor V (factor V:C) and factor VIII (factor VIII:C) were
measured by one-stage clotting assays on a KC10A Amelung
Coagulometer (Amelung GmbH, Lemgo, Germany) and
levels of protein C antigen (PC) by enzyme-linked im-
munosorbent assay (ELISA) (reagents obtained from
DAKO, Glostrup, Denmark). Deficient plasmas for fac-
tor V:C and factor VIII:C assays were delivered by Or-
ganon Teknika Corp., Durham, NC, U.S.A. Pooled nor-
mal plasma for assays was obtained from 65 healthy
volunteers, 51 men and 14 women, mean age 37 years
(range 22-63 years). They all had a negative personal
and family history of either thrombosis or bleeding ten-
dency, did not use oral contraceptives or other drugs, and
were not pregnant within the last 3 months.
Statistics
Patients with established venous thromboembolism
were compared with patients in whom venous thrombo-
embolism could not be demonstrated. Baseline charac-
teristics were summarized to evaluate differences be-
tween the groups. Normally distributed continuous vari-
ables were analyzed with the Student’s t test and
presented by mean and standard deviation. Skewed dis-
tributed continuous variables were analyzed using the
Wilcoxon’s two-sample test and presented as median and
range. Categorical variables were analyzed by Fisher ex-
act test or the chi-square test, when appropriate. To
evaluate changes in time, analysis for repeated measure-
ments was performed using a random effects model (11).
Logistic regression analysis was used to identify covari-
ables related to the occurrence of venous thromboembo-
lism. The results are expressed by odds ratios. Univariate
and multiple regression analysis were performed to as-
sess the influence of clinical and laboratory characteris-
tics on nAPC-SR. Regression coefficients are presented.
All p values are two sided and a p < .05 was considered
statistically significant. Analysis was performed using
SAS software, version 6.12 (SAS-Institute Inc., Cary,
North Carolina, U.S.A.).
RESULTS
The present study included 61 of the 120 patients in
our center who received placebo. Of this group, 20 pa-
tients were excluded from analysis because a bilateral
venogram could not be obtained or was not evaluable (12
patients) or plasma samples were not available (8 pa-
tients). The remaining 41 patients (22 men, 19 women)
had a mean age of 48 years (range 20-73 years). None of
the women were pregnant, one woman used an oral con-
traceptive. A histologic diagnosis was obtained in all
patients with a tumor. Deep vein thrombosis was dem-
onstrated by venography in 10 (24.4%) of 41 evaluable
patients. Five patients had proximal DVT, one patient
had bilateral proximal DVT. None of the patients re-
vealed clinical suspicion of DVT or pulmonary embo-
lism. Baseline characteristics are summarized in Table 1.
Patients who developed DVT were significantly more
often female (p = .03) and had a significantly higher
Quetelet index (p = .01). Age, duration and type of
surgery, and diagnosis were equally distributed among
patients with and patients without DVT. A primary or
metastatic brain tumor was present in 70% of the patients
with DVT and in 84% of patients without DVT. There
were no significant differences in baseline values of
nAPC-SR, factor V:C, factor VIII:C, and PC between the
two groups.
Perioperative nAPC-SR values in both groups are
shown in Fig. 1. A lowered nAPC-SR was observed prior
to surgery in 7 (70%) of 10 patients who developed DVT
and in 24 (77%) of 31 patients without DVT (p = .68).
After surgery, nAPC-SR decreased and was lowered in
all patients (100%) of the DVT group, compared with 23
(74%) and 26 (84%) of patients without DVT at 3 and 7
days after surgery, respectively.
The levels of factor V:C (p = .003), factor VIII:C (p
= .0002), and PC (p = .03) increased significantly after
surgery (Table 2). Changes of factor VIII:C levels were
most pronounced. No differences were demonstrated be-
tween patients with and patients without DVT.
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TABLE 1. Baseline characteristics of 41 patients
QI, Quetelet index; DVT, deep vein thrombosis; nAPC-SR, normalized activated protein C sensitivity ratio;
factor V:C, factor V clotting activity; factor VIII:C, factor VIII clotting activity; PC, protein C antigen. Mean
± SD is given for age, QI and duration of surgery. Median (range) is given for nAPC-SR, factor V:C, factor
VIII:C, and PC.
* Includes decompression of the trigeminal nerve and pituitary tumor surgery.
t Normal range.
Logistic regression analysis showed no relation be-
tween the level of nAPC-SR and the development of
DVT (p = .93, .47, and .47 for nAPC-SR before surgery,
and at 3 and 7 days after surgery, respectively). Female
gender and the Quetelet index (>25 kg/M2) were iden-
tified as independent predictors of DVT; odds ratios
(95% confidence interval) were 12.0 (1.5-100.0; p =
.02) for women versus men and 17.8 (2.3-140.4; p =
.006) for a Quetelet index ?25 kg/M2 versus <25 kg/M2.
An interaction between gender and excess weight could
not be assessed because of the small number of patients.
However, six of eight overweight women developed
DVT and only two of eight overweight men. In contrast,
2 of 11 normal weight women developed DVT and none
of 14 normal weight men.
Multiple regression analysis showed an inverse rela-
tion between nAPC-SR and factor VIII:C (regression co-
FIG. 1. Course of nAPC-SR on the day prior to surgery (-1 ),
day 3 (+3), and day 7 (+7) after surgery, in patients with (0) and
without (0) deep vein thrombosis (DVT). Median values are in-
dicated per group. Horizontal line denotes the lower limit of nor-
mal. nAPC-SR, normalized APC sensitivity ratio.
efficient = 
-0.0004, p = .0003) and between nAPC-SR
and PC (regression coefficient = -0.0008, p = .02).
Women had a lower nAPC-SR than men (regression co-
efficient = 
-0.07, p = .0002). The nAPC-SR was not




This study showed a decreased sensitivity to APC in
80% of neurosurgical patients at 3 days, and in 88% at 7
days after surgery. Remarkably, 76% of the patients al-
ready had a lowered nAPC-SR before surgery. Although
DNA analysis was not done, this finding cannot be ex-
plained by the factor V:QSO6 mutation, as its prevalence
in the Dutch population is approximately 5% (3,4). Prob-
ably <5% of patients carried this mutation, since patients
with a history of DVT had been excluded from the trial.
Therefore, APC resistance as observed in a majority of
the patients probably was acquired. The lowered nAPC-
SR was not due to oral contraceptives or pregnancy,
which are known to be associated with a decreased sen-
sitivity to APC (5-8). A relation with a preoperative
condition seems likely because most patients exhibited
APC resistance I day before surgery. Of clinical baseline
characteristics, only sex influenced the measured values
of nAPC-SR according to previous reports (5,7). Levels ~&dquo;
of factor VIII:C and PC were inversely related to nAPC-
SR. A similar relationship between factor VIII:C and
nAPC-SR has been observed in women who used oral
contraceptives and in pregnant women (6,12). Elevated
baseline levels of factor VIII:C might be due to the dis-
orders for which surgery was performed, mainly brain
tumors and cerebrovascular events or malforma-
tions. The routinely applied perioperative dexametha-
sone therapy in a majority of patients might be an alter-
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TABLE 2. Perioperative values of factor V clotting activity (factor V:C), factor VIII
clotting activity (factor VIII: C) and protein C antigen (PC) on the day prior to surgery
(-1 ) and day 3 (+3) and day 7 (+7) after surgery
Median and range are given. *Normal range. tstatistical significance of overall effect in time.
DVT, deep vein thrombosis.
native explanation. Although this effect of dexametha-
sone has not been reported before, increasing levels of
factor VIII:C have been demonstrated in patients who
received prednisone (13). The less pronounced elevated
baseline PC levels in our patients might similarly be
attributed to this drug (14). Furthermore, elevated PC
levels have been reported in patients with glioblastoma
or brain metastases, as compared with other brain tumors
(15). However, the former tumors were present in only
four of our patients (baseline PC levels 136-180%).
After surgery factor VIII:C levels significantly in-
creased, especially in patients who developed DVT. Lev-
els of factor V:C and PC showed a significant, but slight
increase. Thus, the observed change in nAPC-SR may
have been caused mainly by an incline of factor VIII:C.
Other studies (16,17) showed increasing levels of factor
VIII:C after surgery, whereas factor V:C levels did not
change and PC levels commonly decreased with a nadir
at the second postoperative day. Variation in the postop-
erative course of factor V:C and PC levels can be ex-
plained by a difference in patient handling. Neurosurgi-
cal patients are often made slightly hypovolemic and
hyperosmolar to minimize cerebral edema, while ample
fluid infusion is given in other types of surgery. Hemo-
concentration might have resulted in the observed slight
increase of factor V:C and PC.
Changes in levels of other coagulation and anticoagu-
lant factors that are determinants of the aPTT may also
have contributed to the observed decrease in sensitivity
to APC. Elevated levels of factor IX, for example, have
been demonstrated after surgery for brain tumors (18).
We measured levels of factor V:C, factor VIII:C, and PC,
considering that an imbalance of these proteins might
result in APC resistance, as they are involved in the
protein C anticoagulant pathway. Protein S, though in-
volved in this pathway too, was not taken into account
because its influence on APC ratio remains limited to
levels <20% (4). Whether acquired APC resistance is
explained sufficiently by changing levels of the men-
tioned factors, particularly factor VIII, remains question-
able. In a recent study (8), acquired APC resistance due
to oral contraceptives was demonstrated by measuring
the effect of APC on thrombin formation. In the latter
test, thrombin generation is initiated via the extrinsic
pathway of coagulation (19), whereas in aPTT-based test
systems coagulation is initiated via the intrinsic coagu-
lation pathway. Irrespective of its mechanism, a de-
creased sensitivity to APC, as demonstrated by different
tests and in various conditions recognized as thrombotic
risk factors, supports the concept of acquired APC resis-
tance as a prothrombotic state.
It seems plausible that acquired APC resistance con-
tributes to venous thromboembolism analogous to its
hereditary counterpart. Of nAPC-SR values in the pre-
sented patients, 81 % (preoperatively) to 88% (postopera-
tively) were in the same range as we found in heterozy-
gous carriers of the factor V:QS°~ mutation (0.51-0.83).
A lowered nAPC-SR was not identified as a risk factor
for postoperative DVT, demonstrated by venography in
30% of patients with a normal and in 23 % of those with
a lowered sensitivity to APC.
The small number of the patients is a limitation of this
study. Nevertheless, the results are interesting because it
is the first study addressed to the role of acquired APC
resistance in the development of DVT. Moreover, all
patients were scheduled prospectively for venography
and they did not receive thromboprophylactic drugs. Our
findings emphasize the need for properly designed and
adequately powered clinical studies to establish the clini-
cal relevance of acquired APC resistance. This also re-
gards other thrombotic risk factors that have been asso-
ciated with acquired APC resistance, such as the use of
oral contraceptives and pregnancy (5-7). Recommenda-
tions for clinical practice, based on the supposed causal
relationship of a lower sensitivity to APC with a higher
thrombotic risk of third-generation versus second-
generation oral contraceptives (8,9), are premature in our
opinion until convincing supportive evidence becomes
available.
Our findings show that the applied test to measure
nAPC-SR is not suitable to demonstrate hereditary APC
resistance in neurosurgical patients who exhibit venous
thromboembolism. A modification by predilution of the
test plasma with factor V deficient plasma is one of the
109
alternatives for DNA analysis to reliably identify carriers
of the factor V:QSO6 mutation (20).
CONCLUSION
This study showed that acquired APC resistance is
commonly found in neurosurgical patients who are at
high risk of DVT. However, this in vitro phenomenon
was not related to the development of DVT. Its clinical
relevance in conditions associated with an increased risk
of venous thromboembolism remains to be established.
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